Novel development in extraintestinal manifestations and spondylarthropathy

De Vos M, MD.PhD – Hindryckx P, MD – Laukens D, PhD
Department Gastroenterology
Ghent University Hospital
Belgium

Abstract
The important co-existence of spondylarthitis (SpA) and inflammatory bowel disease (IBD) within the same individual suggests common etiopathogenic mechanisms. This is supported by intriguing similarities between both diseases at the subclinical and molecular level. The recent advances in IBD genetics have led to the identification of common pathways involved in both IBD and SpA, including bacterial recognition and ER stress. This offers the opportunity to develop potential new therapeutic strategies for both diseases. Transgenic animals which develop both joint and gut inflammation (like the TNF^{ΔARE} mice and the HLA-B27 transgenic rats) are a very useful tool to test such novel therapeutics and to get further mechanistic insight into the pathogenetic link between SpA and IBD.

This review will focus on the recent scientific progress in our understanding of the link between SpA and IBD. Based on this, potential novel therapeutic strategies are discussed.
Introduction

The extraintestinal manifestations of inflammatory bowel disease (IBD) include peripheral and axial arthropathy in 20% of patients, skin involvement in 20% of patients, uveitis in 8% and liver disease in 6% of patients. The arthropathy observed in IBD belongs to the concept of spondylarthropathy (SpA) and includes a transient, migratory and mostly non-deforming arthritis and/or an inflammatory back pain associated with sacroiliitis and spondylitis. On the other hand, extra-articular manifestations of SpA include IBD in 20% of patients, psoriasis in 20% of patients and uveitis in 51% of patients. Characteristic for gut, joint, skin and eye disease is the well-proven effect of TNF-α blockers, suggesting a central role of TNF-α in these immune-mediated inflammatory diseases.

Besides the important coincidence of IBD and SpA, an intriguing link between both disorders is found at the subclinical level. On the one hand, asymptomatic sacroiliitis is present on radiography in 16% of patients with IBD. However, when using MRI to detect sacroiliitis, the prevalence will probably be much higher, as it has been demonstrated that the clinical stage of inflammation is preceded by abnormalities on MRI including oedema of the cartilaginous portion of the sacroiliac joint and fat deposition in the subchondral bone marrow followed by the well-known erosions of joint facets and narrowing of joint space [1]. On the other hand, subclinical gut inflammation has been described in 60% of patients with SpA including in 25% of patients a chronic gut inflammation with increased risk for the development of overt IBD [2].

Based on recent literature, this review aims to give an overview of the processes involved in both joint and gut inflammation.
Animal models for the study of combined inflammatory bowel disease and spondylarthritis

TNF\(^\Delta_{\text{ARE}}\) mice

The TNF\(^\Delta_{\text{ARE}}\) mouse model is characterized by a 69 base pair deletion of TNF-\(\alpha\) AU-rich elements from the mouse genome leading to steady-state increased TNF-\(\alpha\) mRNA levels in hematopoietic and stromal cells as well as a diminished translational silencing of the TNF-\(\alpha\) mRNA. Starting at the age of 5 weeks, the animals spontaneously develop an inflammatory disease characterized by CD-like chronic ileitis and SpA-like sacroiliitis, achilles tendon enthesitis and peripheral arthritis. Therefore, this is an ideal model to study the relationship between CD and SpA [3].

Using micro-CT scan after oral gavage with Gastrografin and a micro-Positron Emission Tomography scan (PET) after intravenous injection of 2-deoxy-2(17\(\text{F}\))fluoro-d-glucose, we were able to illustrate and quantify inflammation in the terminal ileum and the joints in this animal model [4]. As such, this technique represents a very attractive tool to study therapeutic interventions (see figure 1).

HLA-B27 transgenic rats

The HLA-B27 transgenic rat model was created by microinjection of the human HLA-B27 and \(\beta_2\)-microglobulin genes into rat zygotes. By expressing HLA-B27 and \(\beta_2\)-microglobulin, these rats develop spondylarthritis, inflammatory bowel disease (which mainly affects the colon), psoriasis vulgaris and genital inflammation [5].

Mechanism based future treatment modalities in IBD and SpA

Two different approaches can be used to shape the fundaments for future treatment modalities in IBD and SpA. Firstly, the search for common susceptibility genes linking different human
immune mediated inflammatory diseases may help to identify potential common etiopathogenetic pathways leading to disease (see figure 2). Secondly, interventional studies in TNF$^{\Delta$ARE} mice and HLA-B27 transgenic rats will be useful to study the effect of potential therapeutics on both gut and joint inflammation.

Common susceptibility genes and associated pathways

CARD15, bacterial recognition and NF$\kappa$B activation

The first susceptibility gene that has been identified for CD is CARD15, also known as NOD2. Variants within this gene increase the risk for CD by threefold for heterozygous individuals and 33-44 fold for homozygous and compound heterozygous individuals. Several studies excluded an association between CARD15 variants and AS or SpA in IBD populations [6-11]. However an association was found in SpA patients between the carriage of CARD15 variants and the development of chronic subclinical gut inflammation, with odds ratio’s of 2.9 as compared to control population and of 5.8 as compared to SpA patients without gut inflammation [11]. Although CARD15 mutations do not seem to predispose to joint inflammation in SpA patients, it might confer a risk towards the development of (sub)clinical gut inflammation, rendering these patients more prone to develop overt IBD. In order to use such a marker to predict patient outcome, long-term follow-up studies are necessary. However, a CARD15-mediated NF$\kappa$B-dependent inflammatory reaction might be an important pathogenic process within the joints [12]. In Blau syndrome, characterized by inflammatory arthritis, uveitis and dermatitis, a definite link was found with the carriage of mutations in the CARD15 gene. The protein is expressed in joint tissue, and bacterial cell wall components have been demonstrated in synovium of SpA patients, supporting the idea that CARD15 can locally trigger inflammation. It has been demonstrated that the activation of CARD15 in synovial fibroblasts from patients with reumatoid arthritis acts synergistically
with Toll like receptors in the production of pro-inflammatory and destructive mediators [13]. Finally, CARD15-deficient mice do not develop arthritis upon direct local challenge with peptidoglycan, whereas wild type mice do [14].

The IL23/T helper 17 (Th17) axis

A second important associated gene complex for IBD that has been identified through genome-wide association is the pathway leading to T helper 17 (Th17) cell development [15]. These T cells produce a specific cytokine pattern, specifically IL17A, IL17F, IL22, TNF-\(\alpha\) and IL6. Differentiation of these TH17 cells is induced by TGFb and IL21, while the perpetuation of the Th17 cell program is mediated by IL23R signalling. Retinoic acid receptor-related orphan receptor gamma (ROR gamma), but also RORalpha was shown to regulate Th17 differentiation [16].

Both protective and risk variants in the IL23R gene have been found associated with both CD and AS [17, 18]. Other variants in genes involved in IL23R signalling and Th17 differentiation have been described in IBD (IL12B, STAT3, JAK2, and CCR6) but their relevance still needs to be studied in SpA.

The functional consequence of genetic variants within the IL23/Th17 axis on the normal execution of this pathway is not well studied. A major draw-back is the low allele frequency of the associated variants, and therefore the lack of sufficiently large numbers of patients to be studied. Nevertheless, it is clear that in general Th17 effector cytokines are aberrantly expressed in affected tissues of patients with CD as well as of patients with AS. A specific expression signature of IL23 an IL17 has been found in patients with subclinical chronic gut inflammation: IL23 gene expression is increased in terminal ileum of AS patients, but unlike in CD, IL17 is not induced [19].
IL17 differentiation and effector cytokines are increased in intestinal mucosa of IBD patients and seems higher in active ulcerative colitis than Crohn colitis [20]. Intriguingly, the expression of Th17 differentiation factors in active Crohn ileitis is not changed as compared to healthy ileal tissue unless for the effector cytokines IL17 and IL22 (unpublished data).

The role of IL17A/IL17F in intestinal inflammatory colitis may be dual: neutralisation of IL17A and/or IL17F in animal models of colitis leads to contradictory results [21, 22]. Together, these findings suggest that a neutralisation of Th17 effector cytokines as therapeutic target or a neutralisation of ROR gamma deserves attention, with possibly different effects in colonic and ileal inflammation.

**HLA-B27 and endoplasmic reticulum stress**

The most studied gene of interest for AS is the HLA-B27 gene. The association of HLA-B27 with arthritis is found in 90% of patients with AS without IBD, 25-70% of patients with AS and IBD but only in 7% of patients with IBD and sacroiliitis and 7% of patients with IBD alone.

In HLA-B27 expressing macrophages, IL23 was synergistically up-regulated in response to lipopolysaccharide stimulation [23]. In addition, IL23 and IL17 were strongly expressed in the colon of HLA-B27 transgenic rats.

The trimer heavy chain of HLA-B27 has a tendency to misfold in the endoplasmic reticulum (ER) and activate the unfolded protein response (UPR) which induces profound changes in the cellular metabolism [24]. One of these changes includes an inhibition of the translation and the transcription of molecular chaperone genes and results in a downstream inflammation [25].

An important role for ER stress in IBD is emerging: association between variants in one of the key components of ER stress (XBP1) with CD and UC has been demonstrated. Moreover a
deletion of XBP1 in intraepithelial cells induces a spontaneous enteritis secondary to Paneth cell dysfunction and over-reactive epithelium to bacterial products and TNF-α [26]. We have recently provided additional evidence supporting a key role of ER stress in both gut and joint inflammation. A study of mucosal gene expression profiles in IBD and SpA patients revealed an aberrant expression of metallothioneins [27]. These are acute stress proteins able to alleviate oxidative-stress induced ER stress in cardiac disease [28-30]. A recent association study in a cohort of 182 AS patients for SNP markers corresponding to 40 CD risk loci described by Barrett and colleagues identified a common association with a locus linked with ORMDL3 gene expression, a gene involved in protein folding and ER stress [31, 32].

**Interventional studies in TNF-ΔARE mice**

*Prolyl hydroxylase inhibitors*

Chronic inflammation is associated with increased consumption and disturbed delivery of oxygen, resulting in profound hypoxia at the site of inflammation [33]. Hypoxia-inducible factor-1 (HIF-1) is the master regulator of cellular responses to low oxygen levels. During hypoxia, HIF-1 is stabilized through inhibition of “oxygen-sensing” prolyl hydroxylases, resulting in an adaptive gene transcription programme, which is essential for both enterocyte and chondrocyte cell function and cell survival [34]. We found that the prolyl hydroxylase inhibitor dimethylxalylglycin (DMOG) protects intestinal epithelial cells against TNF-α-induced cell death through HIF-1-dependent repression of Fas-associated death domain protein (FADD), a critical adaptor protein in TNFR-1-mediated apoptosis [35]. This anti-apoptotic action at least in part contributes to a fast restoration of barrier function and dampening of the chronic intestinal inflammation in TNF-ΔARE mice treated with DMOG. However, DMOG was not effective in the concomitant arthritis of these mice, possibly because DMOG is a non-selective hydroxylase inhibitor which also disturbs proper collagen
formation through interference with collagen hydroxylases [36]. The development of more specific HIF-hydroxylase inhibitors is eagerly awaited.

**CD8αβ lymphocyte inhibitors**

Ileal inflammation is associated with a decline of potentially protective TCRαβCD8αα and TCRγδ lymphocytes early in the disease process and the predominance of TNF/IFN-γ producing CD8αβ lymphocytes in the epithelium [37]. Additionally, a decrease in IFN-γ + CD4 intraepithelial lymphocytes is found. The IFN-γ dependence of the TNFAARE model may be related to IFN-γ producing CD8αβ intraepithelial lymphocytes rather than Th1 CD4 T-lymphocyte response.

In the lamina propria (LP), a significant increased CD4/CD8αβ ratio is observed as compared with wild type mice [37]. Lamina propria CD4 lymphocytes are characterized by decreased expression of IFN-γ and increased expression of IL17 and IL10. CD8αβ lymphocytes from the LP of both normal and diseased animals highly express IFN-γ indicating a decreased Th1 and increased Th17 CD4 T-cell response in the inflamed LP and the persistent capacity of LP CD8αβ lymphocytes for IFN-γ production.

**Selective TNFR1 inhibitors**

Signalling through TNFRI in synovial fibroblasts and intestinal myofibroblasts appeared to be sufficient to develop combined gut and joint inflammation in TNFAARE mice, providing the first strong evidence for a common pathophysiologic mechanism and suggests that attenuation of this pathway may hold promise for more rational and effective therapeutic interventions [38].
**Invariant natural killer T-cell (iNKT cell) activators**

Absence of invariant natural killer T-cells (iNKT cells) aggravates articular and ileal inflammation in TNF-ΔARE mice. Chronic dysregulated TNF-α production activates iNKT cells by influencing their cross-talk with dendritic cells and as such, induces a counter-regulatory mechanism for dampening TNF-α-driven inflammation [39]. Activators of iNKT cells may thus represent a promising therapy for immune-mediated inflammatory disease.

**Leukocyte homing inhibitors**

The selective recruitment of leukocytes from the circulation to the target tissues is controlled through the interaction of adhesion molecules and chemokine receptors with their corresponding ligands. Ileal inflammation is associated with an increased αEβ7 integrin expression in peripheral activated/memory intestinal-homing CD8αβ lymphocytes. A similar enrichment of T cells carrying β7 integrins was found in inflamed synovial tissue from patients with early SpA [40]. Genetic ablation of β7 integrin protects mice against ileitis whereas absence of chemokine/chemokine receptor pair CCL25/CCR9 has no influence on inflammation, supporting the idea that CCR9-independent pathways of T-lymphocyte recruitment to the ileum are responsible for lymphocyte accumulation and disease pathogenesis in CD8-dependent TNF-α-driven CD [37].

**Selective kinase blockade**

Selective blockade of Jun N-terminal Kinase 2 (JNK2) and tumour progression locus 2 (Tp12) kinase is associated with an improvement of enterocolitis, whereas blockade of p38/MAPK-activated protein kinase 2 (p38/MK2) increases intestinal inflammation [41].
Summary

The advances in techniques to study genetic predisposition of complex diseases can significantly aid to understand associated disease manifestations such as arthropathy. In this way, previously unidentified pathways such as bacterial recognition and ER stress were linked with both IBD and SpA. Finally, an elegant way to study these processes and to test therapeutic potential is the use of the TNF$\Delta$ and HLA-B27 transgenic models.

Conflict of interest

None

Acknowledgements

The authors wish to thank Steven Staelens en Steven Deleye (Medical Signal and Image Processing group, Ghent University-IBBT, Ghent, Belgium and Faculty of Medicine, Molecular Imaging Center Antwerp, Antwerp University, Antwerp, Belgium) for acquisition of the PET/CT images.

References


Figure legends

Figure 1: Assessment of intestinal and articular inflammation through non-invasive micro-PET/CT scanning, using FDG as a PET-tracer.

A: mouse positioned for micro-PET/CT scan. B: CT-image after oral contrast (gastrografin) administration, allowing easy identification of the terminal ileum (arrow).

C and D: Detailed CT-images of the terminal ileum of a 16-week old TNF$^{\Delta ARE}$ mouse with (D) and without (C) PET-image overlay. Note the sharp delineated FDG hot spot at the level of the terminal ileum.

E and F: Detailed CT-images of the knee joint of the same animal, with (F) and without (E) PET-image overlay. Note the presence of knee joint inflammation, visualized with FDG-PET.

G: Pictures of H&E-stained terminal ileal sections of the same TNF$^{\Delta ARE}$ mouse (right) and a healthy littermate (left). Note the presence of increased inflammatory cell infiltrations and disturbance of the villous architecture in the TNF$^{\Delta ARE}$ mouse.

H: PET-signal quantification at the level of the terminal ileum of the same TNF$^{\Delta ARE}$ mouse.
mouse and healthy littermate, confirming highly-increased terminal ileal FDG-signal in the TNF$^{\Delta\text{ARE}}$ mouse.

**Figure 2: Common pathways involved in joint- and gut inflammation.**

Apoptosis of intestinal epithelial cells leads to a barrier breakdown. CARD15 is a bacterial receptor in the gut involved in the triggering of NF-$\kappa$B-mediated pro-inflammatory reaction. Th1 and Th17 responses are induced. Polymorphisms in the *CARD15* gene and the *IL23R* gene may modulate this response.

Inflammation is characterized by microvascular dysfunction and an increased influx of oxygen-demanding inflammatory cells releasing pro-inflammatory cytokines like TNF$\alpha$, which increases epithelial apoptosis by binding to TNFRI. Resulting mucosal hypoxia also increases apoptosis of the intestinal epithelial cells and promotes the influx of intraluminal antigens into the lamina propria, which in turn sustains the inflammatory process. Induced endoplasmic reticulum stress further increases epithelial response to bacteriae and intensifies inflammatory reaction.

Activated T cells and macrophages carrying bacterial components migrate to the joints and may be recognized by adhesion molecules such as b7 integrins and VAP-1. CARD15 may recognize bacterial components and induces NF-$\kappa$B-dependent inflammation. The targeted joint mesenchymal cells become activated and sustain inflammation. Finally, circulation of iNKT cells dampens inflammation in gut and joints.